MA53378A - Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète - Google Patents

Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète

Info

Publication number
MA53378A
MA53378A MA053378A MA53378A MA53378A MA 53378 A MA53378 A MA 53378A MA 053378 A MA053378 A MA 053378A MA 53378 A MA53378 A MA 53378A MA 53378 A MA53378 A MA 53378A
Authority
MA
Morocco
Prior art keywords
glp1
gip
against diabetes
agonist against
agonist
Prior art date
Application number
MA053378A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Over Cabrera
Tamer Coskun
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53378A publication Critical patent/MA53378A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
MA053378A 2018-07-23 2019-07-22 Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète MA53378A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702180P 2018-07-23 2018-07-23
US201862730562P 2018-09-13 2018-09-13
US201862740640P 2018-10-03 2018-10-03

Publications (1)

Publication Number Publication Date
MA53378A true MA53378A (fr) 2021-06-02

Family

ID=67544389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053378A MA53378A (fr) 2018-07-23 2019-07-22 Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète

Country Status (25)

Country Link
US (2) US12295987B2 (fr)
EP (2) EP4450127A3 (fr)
JP (3) JP7620601B2 (fr)
KR (2) KR20240095310A (fr)
CN (2) CN112469431A (fr)
AU (2) AU2019309798A1 (fr)
BR (1) BR112020026020A2 (fr)
CA (1) CA3107108A1 (fr)
DK (1) DK3826662T5 (fr)
ES (1) ES2993282T3 (fr)
FI (1) FI3826662T5 (fr)
HR (1) HRP20241479T2 (fr)
HU (1) HUE069270T2 (fr)
IL (2) IL280159B2 (fr)
LT (1) LT3826662T (fr)
MA (1) MA53378A (fr)
MX (2) MX2021000792A (fr)
PL (1) PL3826662T3 (fr)
PT (1) PT3826662T (fr)
RS (1) RS66110B9 (fr)
SG (1) SG11202100116TA (fr)
SI (1) SI3826662T1 (fr)
UA (1) UA129947C2 (fr)
WO (1) WO2020023388A1 (fr)
ZA (1) ZA202212500B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
AU2021312323A1 (en) 2020-07-22 2023-02-02 Novo Nordisk A/S Co-agonists at GLP-1 and GIP receptors suitable for oral delivery
BR112023003668A2 (pt) 2020-10-17 2023-04-25 Sun Pharmaceutical Ind Ltd Agonistas duplos de glp-1/gip
JP2024508745A (ja) * 2021-02-17 2024-02-28 イーライ リリー アンド カンパニー Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024252366A1 (fr) 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg
CN116854805B (zh) * 2023-09-05 2023-12-15 杭州湃肽生化科技有限公司 替尔泊肽的制备方法
WO2026046202A1 (fr) * 2024-08-26 2026-03-05 博瑞生物医药（苏州）股份有限公司 Utilisation d'un peptide glp-1/gip ou composition pharmaceutique la contenant

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556466T3 (es) * 2011-05-13 2016-01-18 Sanofi-Aventis Deutschland Gmbh Lixisenatida y metformina para el tratamiento de la diabetes tipo 2
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
WO2015022420A1 (fr) * 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TWI735917B (zh) * 2018-07-23 2021-08-11 美商美國禮來大藥廠 Gip/glp1共促效劑化合物

Also Published As

Publication number Publication date
CN119499352A (zh) 2025-02-25
IL308674A (en) 2024-01-01
ES2993282T3 (en) 2024-12-26
FI3826662T5 (fi) 2025-03-28
ZA202212500B (en) 2024-10-30
SI3826662T1 (sl) 2025-01-31
EP4450127A3 (fr) 2025-01-01
AU2024202616A1 (en) 2024-07-11
JP2024056852A (ja) 2024-04-23
JP2021530544A (ja) 2021-11-11
CN112469431A (zh) 2021-03-09
US20250241995A1 (en) 2025-07-31
PT3826662T (pt) 2024-10-30
HRP20241479T2 (hr) 2025-03-14
DK3826662T5 (da) 2025-03-24
US12295987B2 (en) 2025-05-13
MX2025007846A (es) 2025-08-01
RS66110B9 (sr) 2025-05-30
HUE069270T2 (hu) 2025-02-28
KR20240095310A (ko) 2024-06-25
EP3826662B1 (fr) 2024-09-11
CA3107108A1 (fr) 2020-01-30
UA129947C2 (uk) 2025-09-24
EP4450127A2 (fr) 2024-10-23
JP2022177118A (ja) 2022-11-30
IL280159A (en) 2021-03-01
MX2021000792A (es) 2021-06-15
LT3826662T (lt) 2024-11-25
JP2025063146A (ja) 2025-04-15
RS66110B1 (sr) 2024-11-29
DK3826662T3 (da) 2024-09-30
US12453758B2 (en) 2025-10-28
SG11202100116TA (en) 2021-02-25
EP3826662A1 (fr) 2021-06-02
EP3826662B9 (fr) 2025-02-19
JP7620601B2 (ja) 2025-01-23
BR112020026020A2 (pt) 2021-03-23
US20230293638A1 (en) 2023-09-21
IL280159B2 (en) 2024-05-01
WO2020023388A1 (fr) 2020-01-30
FI3826662T3 (fi) 2024-11-20
AU2019309798A1 (en) 2021-02-11
HRP20241479T1 (hr) 2025-01-03
ES2993282T9 (en) 2025-03-13
IL280159B1 (en) 2024-01-01
PL3826662T3 (pl) 2025-01-20
KR20210024081A (ko) 2021-03-04

Similar Documents

Publication Publication Date Title
IL284446A (en) Process for preparing a gip/glp1 dual agonist
IL282101A (en) Determining a correction to a process
SG11202100128UA (en) Gip/glp1 co-agonist compounds
SG11202100116TA (en) Method of using a gip/glp1 co-agonist for diabetes
MA53390A (fr) Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
EP3746256C0 (fr) Procede de traitement au laser d'un materiau
GB201811539D0 (en) Fabrication process for a/m/x materials
IL277852A (en) A method for performing a measurement procedure
IL280323A (en) Method for producing cd3-positive cell
DK3530560T3 (da) Apparat til overvågning af et bådedrev
IL290056A (en) Process for producing a tablet comprising glp-1 peptides
DK3741701T3 (da) Fremgangsmåde til fremstilling af et metallisk dåselåg
GB201814369D0 (en) Method for determining a polymersequence
IL280423B2 (en) A method for identifying protein intermediate structures
HUE055363T2 (hu) Eljárás alkaloidtartalmú anyag készítésére
GB2572767B (en) Apparatus for monitoring a measurand
IL291531A (en) A method for activating a cell
DK3543954T3 (da) Fremgangsmåde til behandling af en video
DK3502313T3 (da) Fremgangsmåde til fremstilling af et forkoksningshæmmende krystallinsk materiale baseret på en overflade af rustfrit stål
EP3744772A4 (fr) Procédé de fabrication d'un comprimé poreux
IL280551A (en) Method for processing chemical liquid
SI3802529T1 (sl) Postopek za izdelavo palbocikliba
PL3613684T3 (pl) Sposób obsługi zespołu pomostu przeładunkowego
DK3553212T3 (da) Fremgangsmåde til fremstilling af en krystal af granattypen
DK3605252T3 (da) Indretning, fremgangsmåde og program til at overvåge funktionen af et apparat